DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES

被引：1

作者：

Stopeck, A. T. ^{[1
]}

Richardson, G. ^{[2
]}

Siena, S. ^{[3
]}

Lipton, A. ^{[4
]}

Brown, J. ^{[5
]}

Fizazi, K. ^{[6
]}

Henry, D. ^{[7
]}

Saad, F. ^{[8
]}

Ke, C. ^{[9
]}

Braun, A. ^{[9
]}

机构：

[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA

[2] Cabrini Hosp, Malvern, Vic, Australia

[3] Osped Niguarda Ca Granda, Milan, Italy

[4] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA

[5] Canc Res, UK Clin Ctr, Leeds, W Yorkshire, England

[6] Univ Paris 11, Inst Gustave Roussy, Villejuif, France

[7] Joan Karnell Canc Ctr, Philadelphia, PA USA

[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada

[9] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷

关键词：

D O I：

10.1016/j.ejca.2012.02.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S8 / S8

页数：1

共 50 条

[21] Denosumab versus zoledronic acid in prevention of skeletal-related events in vulnerable cancer patients:a meta-analysis of randomized controlled trials
CHEN Chao-yang
LI Ruo-ming
YANG Ting
MA Ling-yun
ZHOU Shuang
LI Min
ZHOU Ying
CUI Yi-min
中国药理学与毒理学杂志, 2019, (10) : 879 - 880
[22] Skeletal-related events in patients with solid tumors receiving denosumab or zoledronic acid by baseline pain status: Results from three phase 3 trials
Von Moos, R.
Stopeck, A.
Fizazi, K.
Cleeland, C.
Brown, J. E.
Oudard, S.
Costa, L.
Wang, H.
Braun, A.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S268 - S268
[23] Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials
Chen, Chaoyang
Li, Ruoming
Yang, Ting
Ma, Lingyun
Zhou, Shuang
Li, Min
Zhou, Ying
Cui, Yimin
CLINICAL THERAPEUTICS, 2020, 42 (08) : 1494 - +
[24] Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study
Abdel-Rahman, Omar
EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 757 - 761
[25] Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Stopeck, Alison
Brufsky, Adam
Kennedy, Lisa
Bhatta, Sumi
Bhowmik, Debajyoti
Buchanan, Jacqueline
Despiegel, Nicolas
Hechmati, Guy
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 37 - 47
[26] Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer
Henry, D. H.
von Moos, R.
Hungria, V.
Costa, L.
Woll, P. J.
Scagliotti, G.
Wang, J.
Jun, S.
Dansey, R. D.
Yeh, H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors: Incremental Benefit, Debatable Value
West, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1095 - 1098
[28] Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.
Shirina, N.
Coleman, R. E.
Chen, Y. M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 475S - 475S
[29] COMPARING THE EFFICACY OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SRES): A CRITICAL APRAISAL OF THREE PIVOTAL TRIALS
Strite, S.
Stuart, M. E.
Beckman, V
Oehrling, K.
VALUE IN HEALTH, 2015, 18 (03) : A192 - A193
[30] DENOSUMAB VERSUS ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH METASTATIC BONE DISEASE: SUBGROUP ANALYSES BY BASELINE CHARACTERISTICS
Stopeck, A.
Lipton, A.
Fizazi, K.
Smith, M. R.
Shore, N. D.
Martin, M.
Vadhan-Raj, S.
Zhou, K.
Balakumaran, A.
Braun, A. H.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 50 - 50

← 1 2 3 4 5 →